New modalities and aspects of antiplatelet therapy for stroke prevention

Cerebrovascular Diseases

Volumn 21, Issue SUPPL. 1, 2006, Pages 7-16

  Uchiyama, Shinichiro ^a   Nakamura, Tomomi ^a   Yamazaki, Masako ^a   Kimura, Yumi ^a   Iwata, Makoto ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Aspirin resistance; Cilostazol; Combination therapy; GP IIb IIIa inhibitor; Molecular target; Pleiotropic effect; Thienopyridine

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; TICLOPIDINE; TIROFIBAN; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG POTENTIATION; HEART INFARCTION; HUMAN; LOW DRUG DOSE; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STROKE; THROMBOCYTOPENIA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

ASPIRIN; BLOOD PLATELETS; CEREBROVASCULAR ACCIDENT; DRUG DESIGN; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TETRAZOLES; TICLOPIDINE;

EID: 32844467799     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090357     Document Type: Review

References (39)

1. World Heath Organization: Reducing healthy life. World Health Report 2002. http://www.who.int/entity/whr/2002.
2. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
3. Hankey GJ, Eikelboom JW: Aspirin resistance. BMJ 2004;328:477-479.
4. Uchiyama S, Nagayama T, Sone R, Shibagaki Y, Kobayashi I, et al: Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia. Stroke 1989;20:1643-1647.
5. Hankey GJ, Sudlow CLM, Danbabin DW: Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000;31:1779-1784.
6. Hollopeter G, Jantzen HM, Vincent D, Vincent D, Li G, England L, et al: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-207.
7. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
8. Uchiyama S, Yamazaki M, Maruyama S, Handa M, Ikeda Y, et al: Shear-induced platelet aggregation in cerebral ischemia. Stroke 1994;25:1547-1551.
9. Gotoh F, Tohgi H, Hirai S, et al: Cilostazol Stroke Prevention Study. A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9:147-157.
10. Sorkin EM, Markham A: Cilostazol. Drugs Aging 1999;14:63-73.
11. Umekawa H, Tanaka T, Kimura Y, Hidaka H: Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography. Biochem Pharmacol 1984;33:3339-3344.
12. Inoue T, Sohma R, Morooka S: Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro. Thromb Res 1999;93:137-143.
13. Nomura S, Shouzu A, Omoto S, Hayakawa T, Kagawa H, et al: Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost 1998;80:388-392.
14. Mochizuki Y, Oishi M, Mizutani T: Effects of cilostazol on cerebral blood flow, P300, and serum lipid levels in the chronic stage of cerebral infarction. J Stroke Cerebrovasc Dis 2001;10:63-69.
15. Nakamura T, Houchi H, Minami A, Sakamoto S, Tsuchiya K, et al: Endothelial-dependent relaxation by cilostazol, a phosphodiesterase III inhibitor, on rat thoracic aorta. Life Sci 2001;69:1709-1715.
16. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, et al: Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992;20:900-906.
17. Mizutani M, Okuda Y, Yamashita K: Effect of cilostazol on the production of platelet-derived growth factor in cultured human vascular endothelial cells. Biochem Mol Med 1996;57:156-158.
18. Aoki M, Morishita R, Hayashi S, Jo N, Matsumoto K, et al: Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 2001;44:1034-1042.
19. Kim KY, Shin HK, Choi JM, Hong KW: Inhibition of lipopolysaccaride- induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 2002;300:709-715.
20. Nishio Y, Kashiwagi A, Takahara N, Hidaka H, Kikkawa R: Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-α in vascular endothelial cells. Horm Metab Res 1997;29:491-495.
21. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, et al: Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-κB binding to its recognition sequence. Atherosclerosis 2001;158:121-128.
22. Uchiyama S, Yamazaki M, Iwata M: Remnant lipoprotein and lipoprotein (a) as risk factors for stroke and carotid disease; in Matsuzawa Y, Kita T, Nagai R, Teramoto T (eds): Atherosclerosis XIII. Proceedings of the 13th International Atherosclerosis Symposium. International Congress Series 1262. Amsterdam, Elsevier, 2004, pp 478-481.
23. Yamazaki M, Uchiyama S, Xiong Y, Nakano T, Nakamura T, Iwata M: Effects of remnant-like particle on shear-induced platelet activation and its inhibition by antiplatelet agents. Thromb Res 2005;115:211-218.
24. Kimura Y, Uchiyama S, Iwata M: Effects of antiplatelet agents on hemorheology in a microcirculation model. 5th World Stroke Congress, Vancouver, 2004.
25. Coller BS: Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001;86:427-443.
26. Abciximab Emergent Stroke Treatment Trial (AbEST) Investigators: Emergency administration of abciximab for treatment of patients with acute ischemic stroke. Results of a randomized phase 2 trial. Stroke 2005;36:880-890.
27. Topol EJ, Easton JD, Harrington RA, Amarenco P, Califf R, et al: Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:16-23.
28. Uchiyama S, Nakamura T, Yamazaki M, Tsutsumi Y, Iwata M: Platelet activation and antiplatelet therapy in patients with ischemic stroke; in Satoh K, Suzuki S, Matsunaga M (eds): Advances in Brain Research. Cerebrovasclar Disorders and Neurodegeneration. Excerpta Medica International Congress Series 1251. Amsterdam, Excerpta Medica, 2003, pp 57-70.
29. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, et al: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
30. Nakamura T, Uchiyama S, Yamazaki M, Iwata M: Effects of dipyridamole and aspirin on shear-induced platelet aggregation in whole blood and platelet-rich plasma. Cerebrovasc Dis 2002;14:234-238.
31. Uchiyama S, Nagayama T, Sone R, et al: Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia. Stroke 1989;20:1643-1647.
32. Yamazaki M, Uchiyama S, Iwata M, et al: Measurement of platelet fibrinogen binding and P-selectin expression by flow cytometry in patients with cerebral infarction. Thromb Res 2001;104:197-205.
33. Diener HC, Bogouslavsky J, Brass LM, Cimminiello C, Csiba L, et al; on behalf of the MATCH investigators: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337.
34. Kwon SU, Cho Y-J, Koo JS, Bae HJ, Lee YS, et al: Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis. The multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005;36:782-786.
35. Whilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, et al: Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003;38:710-713.
36. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, et al; for the Warfarin-Aspirin Symptomatic Intracranial Disease Study Group: The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995;45:1488-1493.
37. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Herzberg VS, et al; for the Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305-1316.
38. Bhatt DL, Topol EJ: Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003;2:15-28.
39. Jackson SP, Schoenwaelder SM: Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2003;2:775-789.